Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.01
- Piotroski Score 3.00
- Grade Buy
- Symbol (BLCO)
- Company Bausch + Lomb Corporation
- Price $19.80
- Changes Percentage (2.17%)
- Change $0.42
- Day Low $19.33
- Day High $19.83
- Year High $21.69
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $23.00
- High Stock Price Target $25.00
- Low Stock Price Target $18.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.96
- Trailing P/E Ratio -15.96
- Forward P/E Ratio -15.96
- P/E Growth -15.96
- Net Income $-260,000,000
Income Statement
Quarterly
Annual
Latest News of BLCO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Bausch + Lomb Corporation (BLCO) Stock Price, News, Quote & History - Yahoo Finance
Bausch + Lomb is considering a sale to address separation issues from parent company Bausch Health. Lenders like Apollo Global Management oppose the move, despite analysts supporting it due to valuati...
By Yahoo! Finance | 2 months ago
